BioSpace News Archive

DNA synthesizers are systems used to build DNA molecules containing a particular sequence of nucleotides. Synthesizers can create specific DNA molecules for use in the treatment of various diseases by replacing a faulty or damaged section of DNA with a repaired section.

Industry veteran brings deep experience growing companies, including as chairman and CEO of Bristol Myers Squibb, and as board member and CFO of Eli Lilly

Virtual Incision Corporation, a medical device company pioneering a first-of-its-kind miniaturized surgical platform, today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) for the company’s MIRA® (“miniaturized in vivo robotic assistant”) Platform.

Eagle Genomics, a pioneer in applying network science to biology – particularly linked to the microbiome – has closed $9 million in new scale-up funding

Inscripta, Inc., the digital genome engineering company, today announced the appointment of Sri Kosaraju as President and CEO

Predictive Oncology Inc. (NASDAQ: POAI) today announces that its chief executive officer, Carl Schwartz, has been featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”)

SFJ Pharmaceuticals® (“SFJ”) is pleased to note that its partner Apellis Pharmaceuticals Inc. (“Apellis”) (Waltham, MA) and Swedish Orphan Biovitrum AB (“Sobi™") (Stockholm, Sweden) today announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy

DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020.

For anyone who has a family history of Age-Related Macular Degeneration (AMD), a disease that causes blindness, Visible Genomics has introduced a new non-invasive genetic eye test that determines the likelihood of developing AMD.

Urovant Sciences (Nasdaq: UROV) announced today that it will report financial results for its fiscal quarter ended September 30, 2020 after the close of U.S. financial markets on Monday, November 2, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s